Gentronix Ltd.

View all Products

GreenScreen HC
Gentronix has launched a new, accurate and fast in vitro mammalian cell genotoxicity assay - GreenScreen HC. The TK6 host ...

View Product

GreenScreen HC - S9 (Human Cells) a...
In 2008 Gentronix launches a new S9 protocol to extend the application of the GreenScreen HC assay to include the detection of ge...

View Product

BlueScreen HC: The luminescent adap...
BlueScreen HC is based on the fast, accurate GreenScreen HC genotoxicity assay from Gentronix Ltd. BlueScreen HC uses the same human-...

View Product

BlueScreen HC - S9
BlueScreen HC uses a single cell strain, which permits 8 compounds to be tested across 8 dilutions (2-fold serial), together with untreated...

View Product

Predictive Toxicology Package
The cost of drug discovery continues to rise while the output of new NDAs continues to fall. Consequently it has never been more important ...

View Product

Browse All Gentronix Ltd. Products (see all)

Browse Products by Field

Basic Research (5)

Lead Discovery (3)

Life Sciences (5)

Pre-Clinical Development (5)

Target Discovery (5)

Company Profile

Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.

Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.